

JNJ-39758979

Catalog No: tcsc0020957

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Directions

 $\mathsf{C}_{11}\mathsf{H}_{19}\mathsf{N}_5$

Pathway: Immunology/Inflammation;GPCR/G Protein

Target:

Histamine Receptor; Histamine Receptor

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

221.3

Copyright 2021 Taiclone Biotech Corp.



Product Description

JNJ-39758979 is a selective, high-affinity **histamine** H₄ receptor antagonist with a K_i of 12.5 nM.

IC50 & Target: Ki: 12.5 nM (histamine H_a receptor)^[1]

In Vitro: JNJ-39758979 is a selective, high-affinity histamine H₄ receptor antagonist with a K_i of 12.5 nM.

The affinity of JNJ-39758979 for the rat (K_i =188 nM) and guinea pig H₄R (K_i =306 nM) is moderate, and JNJ-39758979 has little if any affinity for the dog H₄R (K_i ≥10 µM). JNJ-39758979 is metabolically stable ($t_{1/2}$ >120 min) when incubated *in vitro* with human, rat, dog, or monkey liver microsomes^[1].

In Vivo: JNJ-39758979 shows dose-proportional pharmacokinetic (PK) in rat in the range of 2 to 500 mpK. JNJ-39758979 rapidly reaches the kidneys and liver (mean t_{max} =2.0 h). The elimination of JNJ-39758979 is slow from the brain, liver, and kidneys, with mean $t_{1/2}$ values of 42.5, 22.3, and 20.5 h, respectively. The highest exposure (based on C_{max} and AUC_{0-inf} values) is observed in the liver followed by the kidney and brain. Tissue-to-plasma ratios for liver and kidney range from 23.2 to 95.8; the tissue-to-plasma ratios in brain increases with time from 0.256 to 22.7 up to 48 h after dosing. JNJ-39758979 is able to inhibit histamine-induced itch at doses of 5 and 20 mg/kg in mice. JNJ-39758979 exhibits dose-dependent inhibition of the clinical score in a mouse collagen-induced arthritis model^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.